Viewing Study NCT03185039



Ignite Creation Date: 2024-05-06 @ 10:10 AM
Last Modification Date: 2024-10-26 @ 12:26 PM
Study NCT ID: NCT03185039
Status: UNKNOWN
Last Update Posted: 2020-01-10
First Post: 2017-06-09

Brief Title: Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Sponsor: Institut Paoli-Calmettes
Organization: Institut Paoli-Calmettes

Study Overview

Official Title: Study of the Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents Compared to Patients Not Treated With Antiangiogenic Localized Kidney Cancer and Oligometastatic
Status: UNKNOWN
Status Verified Date: 2020-01
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Prospective research of Matrix Metalloproteinases MMP 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents Sunitinib or Pazopanib
Detailed Description: The objective is to analyze the predictive impact of circulating MMP2 and MMP9 on the progression-free survival of patients with metastatic kidney cancer treated with anti-angiogenic agents Sunitinib or Pazopanib in comparison with two untreated cohorts localized or oligometastatic cancer

Prospective monocenter open-label study

In the frame of disease management blood samples will be collected at different times of follow-up regarding disease status localized oligometastatic and metastatic and tissue samples will be collected for patients scheduled for surgery

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None